Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind

Cancers

Nicky D’Haene¹  Pieter Demetter²  Christelle Bouchart³  Jean-Luc Van Laethem⁴  Francesco Puleo⁴  Tatjana Arsenijevic⁴  Remy Nicolle⁵ 

[1] Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium;Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium;Department of Radiation-Oncology, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium;Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium;Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, 75013 Paris, France;

关键词: pancreatic ductal adenocarcinoma;    microbiota;    prognostic and predictive biomarkers;    resistance to therapy;   

DOI  :  10.3390/cancers13061231

来源: DOAJ

【 摘 要 】

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer with a dismal prognosis. The five-year survival rate has not changed significantly in over 40 years. Current first-line treatments only offer a modest increase in overall survival in unselected populations, and there is an urgent need to personalize treatment in this aggressive disease and develop new therapeutic strategies. Evolving evidence suggests that the human microbiome impacts cancerogenesis and cancer resistance to therapy. The mechanism of action and interaction of microbiome and PDAC is still under investigation. Direct and indirect effects have been proposed, and the use of several microbiome signatures as predictive and prognostic biomarkers for pancreatic cancer are opening new therapeutic horizons. In this review, we provide an overview for the clinicians of studies describing the influence and associations of oral, gastrointestinal and intratumoral microbiota on PDAC development, progression and resistance to therapy and the potential use of microbiota as a diagnostic, prognostic and predictive biomarker for PDAC.

【 授权许可】

Unknown